These data demonstrate that TLR4 signaling promotes NAFLD progression, and inhibition of LPS release from the intestinal microbiota or usage of TLR4 signaling antagonism may be a feasible strategy for the prevention or treatment of NAFLD/NASH. This evidence concerns the gene TLR4 and metabolic dysfunction-associated steatotic liver disease.